Minimal clinically important differences in COPD lung function.
about
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyIndacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary diseaseSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta 2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseaseEfficacy and safety of sirolimus in lymphangioleiomyomatosis.Tai Chi for chronic obstructive pulmonary disease (COPD)Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary diseaseOnce-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacyClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPDAsthma outcomes: pulmonary physiology.Application of a theoretical model to evaluate COPD disease managementRescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis.Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.Comparison of distinctive models for calculating an interlobar emphysema heterogeneity index in patients prior to endoscopic lung volume reduction.Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneIndacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.Perfusion scintigraphy and patient selection for lung volume reduction surgeryIndacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialLung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial.A novel model-based approach for dose determination of glycopyrronium bromide in COPDSimilar relation of age and height to lung function among Whites, African Americans, and Hispanics.Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary diseaseEffects of Tai Chi in patients with chronic obstructive pulmonary disease: preliminary evidence.Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseLong-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysemaEffects of yoga training in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.Spirometry for patients in hospital and one month after admission with an acute exacerbation of COPD.V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical resultsCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis.Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.Bronchoscopic lung volume reduction by endobronchial valve in advanced emphysema: the first Asian report.Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD.
P2860
Q21257191-CF393056-EE77-4C56-8E31-B4C02D507E3EQ24186652-5E857193-CB0F-4CD0-A370-3CF1A4A33A9DQ24193908-07437BE7-424A-4FA8-B547-0AE6271EE2C6Q24202510-9F1B13C3-0CF5-4C21-A1DE-EBB7A6FA8AADQ24202545-ABA26869-65C2-4823-8C35-8D1C11E9F366Q24234493-75A382A6-E404-4B63-B7A3-B91424A73AA0Q24241135-80E9013F-F3F5-4531-AF81-188C4B59895EQ24610039-F55044C7-D7DE-4C5E-B082-D43EB0A134D2Q26471513-7172AAC4-A049-4CC3-A583-DB53D3176D62Q26745663-01692E9C-278C-43BE-A9A4-3DDDBC48D7EBQ27010444-09E4F15B-92DC-4D4C-8A5D-C44201E9D404Q27023223-287358BE-85DA-4C4A-B38A-F7FF04179ECBQ28596637-E7ECC355-8592-4A35-B3DD-E7D5E06CB157Q30423167-555A200E-4C83-4220-9E93-CC99A9634665Q33546690-0328F715-94F7-4B93-BB49-037A6948852CQ33651564-12CCDC54-460A-412B-9120-0D6E50924C22Q33743284-0A3F5D72-A525-43F2-B355-9842534987E8Q33766537-A50BF009-1C3B-4DFB-B0DB-AF3D205FF281Q34128947-40DA44AB-7936-4F82-8CCB-0C0E941326DDQ34243574-D899B673-CB61-4879-9C12-13EEA11F5CA8Q34269056-DDDC39DF-514F-4D50-AB46-B57ACB054D9EQ34340387-049ED055-83E7-47A6-AA06-6DCF2A0B8AA5Q34380247-8449CF18-8B7E-4D1F-A4BE-265F858AAEEFQ34431346-E12C2CB2-6C76-4CED-A7EC-7D9612449E9AQ34502782-65245AD8-117D-496B-8232-7E19C0F86DEDQ34547704-A0D65898-96D6-4CC7-A1E3-A91D41F4B44FQ34554816-5ECC7171-9358-4ADA-858D-D6F681F104ABQ34692385-4220A5E2-1216-404D-B8A1-EBF4E15211E5Q34753755-D1AA73F7-6BDA-4CF3-A770-93076D46F85EQ34957303-961D5843-1253-48BF-BEBC-407961A55E68Q34995066-9CB6BB87-BC43-42C0-98EE-E8A3EABC69DBQ35061967-77604109-47F4-4CAA-B301-CF1C10896AA0Q35197384-408E6CD8-811F-493C-915E-80B8C543DC56Q35508619-03B1A983-CA3F-45EA-BCCA-B2DFEF89DCBAQ35710238-3FE6170F-05A6-4068-85B1-0ADEB046301FQ35782210-B0E590D4-3AE9-4616-B6C0-6F057F304B51Q35822151-5A9DC8FF-7661-44F9-8934-64730696B6E9Q35914790-5F334B11-B1E2-423D-A82C-F7B6BC8FF5FFQ36052200-ACAC4E20-CA09-4B0E-9E3C-747C37508BEFQ36083119-DB5CE36F-2879-4CDB-92B1-6C07132F2D70
P2860
Minimal clinically important differences in COPD lung function.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Minimal clinically important differences in COPD lung function.
@ast
Minimal clinically important differences in COPD lung function.
@en
type
label
Minimal clinically important differences in COPD lung function.
@ast
Minimal clinically important differences in COPD lung function.
@en
prefLabel
Minimal clinically important differences in COPD lung function.
@ast
Minimal clinically important differences in COPD lung function.
@en
P2860
P356
P1476
Minimal clinically important differences in COPD lung function.
@en
P2093
James F Donohue
P2860
P304
P356
10.1081/COPD-200053377
P407
P577
2005-03-01T00:00:00Z